Daily adjunctive therapy with the investigational oral drug perampanel significantly reduced the frequency of seizures by 5%-14%, compared with placebo. The data come from a multinational phase III clinical trial of 388 patients with hard-to-control epilepsy that was presented at the annual meeting of the American Academy of Neurology.
Patients in the study had uncontrolled epilepsy despite being on one to three other antiseizure drugs, and they continued their usual medications during the trial, according to study investigator Dr. Jacqueline A. French.
Our reporter Sherry Boschert talked with Dr. Marc Nuwer, professor of neurology at the University of California, Los Angeles, who said that the most exciting thing about perampanel is that it establishes a new category of drugs.
You can read more about the study by visiting Clinical Psychiatry News online.